Kinetic Aspects of the Interaction of Blood Clotting Enzymes

H. C Hemker; J. J Veltkamp; E. A Loeliger

doi:10.1055/s-0038-1651213

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1968; 19(03/04): 346-363
DOI: 10.1055/s-0038-1651213

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Kinetic Aspects of the Interaction of Blood Clotting Enzymes

III. Demonstration of an Inhibitor of Prothrombin Conversion in Vitamin K Deficiency

Authors

H. C Hemker

¹Laboratory of Coagulation Biochemistry, Hematology Section, Department of Internal Medicine, University Hospital, Leyden, The Netherlands
J. J Veltkamp

¹Laboratory of Coagulation Biochemistry, Hematology Section, Department of Internal Medicine, University Hospital, Leyden, The Netherlands
E. A Loeliger

¹Laboratory of Coagulation Biochemistry, Hematology Section, Department of Internal Medicine, University Hospital, Leyden, The Netherlands

Abstract

Summary

Application of enzyme kinetics to the results of thrombotest estimations in correlation with specific clotting factor estimations has led to the recognition of a protein moiety that occurs in plasma in vitamin K deficiency and acts as a competitive inhibitor of thrombin formation. A hypothesis is given by which the occurrence of this inhibitor is explained in terms of a biphasic synthesis of the vitamin K-dependent clotting factors.

Full Text

References

References
1 Bachmann F, Duchert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. (Stuttg.) 1958; 2: 24
2 Biggs R. The point of view of the individual as a scientific author. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; 15: 603
3 Borchgrevink G.F, Pool J.G, Stormorken H. A new assay for Factor V (Proaccelerin-accelerin) using Russell's viper venom. J. Lab. clin. Med. 1960; 55: 625
4 Cook G.M.W, Laico M.T, Eylar E.A. Biosynthesis of glycoproteins of the Ehrlich ascitis carcinoma cell membranes. Proc. Nat. Acad. Sci. 1965; 54: 247
5 Hemker H.C, Veltkamp J.J, Hensen A, Loeliger E.A. On the nature of prothrombin biosynthesis. Nature (Lond.) 1963; 200: 589
6 Hemker H.C. Preprothrombin (Complex?.), a circulating anticoagulant in coumarin treated and vitamin K deficient patients. Thrombos. Diathes. haemorrh. (Stuttg.), Suppl. 1964; 13: 380
7 Hemker H.C, Hemker P.W, Loeliger E.A. Kinetic aspects of the interaction of blood clotting enzymes. I. Derivation of formulas. Thrombos. Diathes. haemorrh. (Stuttg.) 1965; 13: 155
8 Hemker H.C, van der Meer J, Loeliger E.A. Differentiële leverfunctie bepaling met behulp van de thrombotest van Owren. Ned. T. Geneeskunde 1965; 109: 646
9 Hemker H.C, Siepel T.V, Altman R, Loeliger E.A. Kinetic aspects of the interaction of blood clotting enzymes. II. The relation between clotting time and plasma concentration in prothrombin-time estimations. Thrombos. Diathes. haemorrh. (Stuttg.) 1967; 17: 349
10 Loeliger E.A. Über den Nachweis eines neuen Gerinnungsfaktors: Faktor V.I.I. Thesis Wien Z. inn. Med 1952; 33: 169
11 Loeliger E.A, Koller F. Behaviour of factor VII and prothrombin during late pregnancy and in the newborn. Acta haemat. (Basel) 1952; 7: 157
12 Loeliger E.A, van der Esch B, Mattern M.J, den Brabander A.S.A. Behaviour of factors II, VII. IX, and X during long-term treatment with coumarin. Thrombos. Diathes. haemorrh. (Stuttg.) 1963; 9: 74
13 Loeliger E.A, Hensen A. Grundlagen erfolgversprechender Langzeitbehandlung mit Coumarin. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 1964; 12: 111
14 Loeliger E.A, Hensen A, Mattern M.J, Hemker H.G. Factors II, VII. IX, and X in bleeding complications during long-termtreatment with coumarin. Thrombos. Diathes. haemorrh. (Stuttg.) 1964; 10: 278
15 Loeliger E.A, Hensen A, Kroes F, van Dijk L.M, Fekkes N, Hemker H.G. A double-blind study of phenprocoumon prophylaxis in coronary heart disease. Acta med. Scand. 1967; 182: 549
16 Magnusson S. Preparation and carbohydrate analysis of bovine prothrombin. Arkiv föř Kemi 1965; 23: 285
17 Marciniak E, Seegers W.H. Prethrombin as a new subunit of prothrombin. Nature (Lond.) 1966; 209: 621
18 Matthews J.M, Walker W. Control of anticoagulant therapy. A trial of thrombotest. Lancet 1959; II: 1159
19 Molnar J, Robinson G.B, Winzler R.J. Biosynthesis of Glycoproteins. IV. The subcellular sites of incorporation of glucosamine -1-¹⁴C into glycoprotein in rat liver. J. biol. Chem. 1965; 240: 1882
20 Olson R.E, Vitamin K. induced prothrombin formation antagonism by Actinomycin D. Science 1964; 145: 926
21 Olson R.E. Personal communication 1966
22 Owren P.A, Aas K. The control of Dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 1951; 3: 169
23 Owren P.A. Thrombotest, a new method for controlling anticoagulant therapy. Lancet 1959; 11: 754
24 Owren P.A. Tests for control of anticoagulant therapy. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 1964; 13: 369
25 Proc. Symp. on recent advances in research on vitamins K and related Quinones. Vitamins and Hormones Vol. 24.
26 Prydz H. Some characteristics of purified Factor VII preparations. Scand. J. clin. Lab. Invest. 17, Suppl. 1965; 84: 78
27 Ray G.C, Chukravarty N.N, Ray S.G. Prothrombin and its relation to vitamin K. Ann. biochem. exp. Med. (Calcutta) 1962; 22: 317
28 Shanberge J.N. The effect of Dicumarol on certain factors in blood coagulation. J. Lab. clin. Med. 1956; 48: 218
29 Schnitger H, Gross R. Über ein Universalgerät zur automatischen Registrierung von Gerinnungszeiten. Klin. Wschr. 1954; 1011
30 Seegers W.H, Gross R. Prothrombin.. Cambridge: Harvard University Press; 1962
31 Tishkojf G.H, Pechet L, Alexander B. Some biochemical and electrophoretic studies on purified prothrombin. Factor VII and Factor X. Blood 1960; 15: 778